Method for administering omega-conopeptide
View Patent ↗The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
1. A method for treating severe chronic pain in a human patient, comprising:
(a) selecting a human patient suffering from severe chronic pain who has an implantable pump;
(b) recommending against admixing an ω-conopeptide and an opioid in the pump, wherein said opioid is selected from the group consisting of morphine and hydromorphone;
(c) administering to the human patient a therapeutically effective amount of an ω-conopeptide by continuous intrathecal infusion using the pump, and
(d) administering to the human patient a therapeutically effective amount of the opioid.
2. The method of claim 1 , wherein the opioid is morphine.
3. The method of claim 2 , wherein the therapeutically effective amount of morphine is a daily dosage of between 0.6 and 4.8 μg per day.
4. The method of claim 1 , wherein the ω-conopeptide is ziconotide.
5. The method according to claim 4 , wherein said ziconotide is administered in a pharmaceutical composition comprising an antioxidant.
6. The method according to claim 5 , wherein said antioxidant is methionine.
7. The method according to claim 5 , wherein said pharmaceutical formulation has pH between 4 and 4.5.
8. The method of claim 5 , wherein the stability of ziconotide is higher than 90% for 14 days.
9. The method of claim 5 , wherein the stability of ziconotide is higher than 80% for 28 days.
10. The method of claim 5 , wherein the stability of ziconotide is higher than 80% for 32 days.
11. A method for treating severe chronic pain in a human patient, comprising:
(a) selecting a human patient suffering from severe chronic pain who has an implantable pump;
(b) not recommending admixing ziconotide and morphine in the pump;
(c) administering to the patient a therapeutically effective amount of a ziconotide formulation at a dose between 0.6-27.9 μg per day by continuous intrathecal infusion using the pump wherein said ziconotide formulation comprises methionine; and
(d) administering to the patient a therapeutically effective amount of the opioid.
12. The method of claim 11 , wherein the stability of the ziconotide is higher than 90% for 14 days.
13. The method of claim 11 , wherein the stability of the ziconotide is higher than 80% for 32 days.
14. The method of claim 11 , wherein morphine is avoided to be admixed with ziconotide to enhance the stability of ziconotide.